NASDAQ: IKT

How many employees work at Inhibikase Therapeutics?

Inhibikase Therapeutics, Inc. (IKT) has approximately 40 total employees worldwide as of March 2026, according to Revelio Labs workforce intelligence data. Inhibikase Therapeutics’s total headcount has grown 213.4% from 13 employees in 2023 to 40 in 2026.

Data source: Revelio LabsCoverage: Global workforce, 20232026Published August 2026

Is Inhibikase Therapeutics hiring right now?

No, Inhibikase Therapeutics is not actively hiring. Inhibikase Therapeutics had 0 active job postings in 2026, a 0.0% no change from 2025 see job openings & hiring trends.

About Inhibikase Therapeutics’s Workforce

Inhibikase Therapeutics, Inc. (IKT) is a Pharmaceuticals company that employs 40 people worldwide as of March 2026. It is the 4th-largest by headcount among its peers. Founded in 2008, the company is headquartered in Wilmington, Delaware and trades on the NASDAQ.

Inhibikase Therapeutics's workforce has grown 213.4% from 2023 to 2026, up 4.1% year over year in 2026. Its workforce is concentrated most in North America (94.2%), followed by Western Europe (5.8%).

Inhibikase Therapeutics's functional groups are Finance and Operations (42.3%), Sales and Marketing (41.7%), and Engineering (16.0%), with Sales and Marketing growing fastest (up 35.6%). The average salary is $205,203, highest in North America at a median of $219,000, up 3.9% year over year in 2026.

Inhibikase Therapeutics's hiring activity held steady in 2026.

Sourced from Revelio Labs workforce data.

Ticker
NASDAQ: IKT
Headquarters
Wilmington, Delaware
Founded
2008
Industry
Pharmaceuticals
Employees
40
YoY
+4.1% (+17)

Unlock hiring rate, attrition rate, and 12 additional workforce metrics for Inhibikase Therapeutics. Compare to peers, export the dataset, and access the full quarterly history.

Unlock Metrics

Inhibikase Therapeutics Annual Employee Count (2023-2026)

Interactive chart of Inhibikase Therapeutics annual worldwide employee count from 2023 to 2026.
  • Inhibikase Therapeutics had 40 employees in 2026, a 4.1% increase (+17) from 2025.
  • Inhibikase Therapeutics had 33 employees in 2025, a 5.5% increase (+18) from 2024.
  • Inhibikase Therapeutics had 15 employees in 2024, a 0% no change (+2) from 2023.
  • Inhibikase Therapeutics had 13 employees in 2023, a 10.9% increase (+3) from 2022.

Inhibikase Therapeutics's total workforce has grown from 13 employees in 2023 to 40 in 2026.

Inhibikase Therapeutics, Inc. quarterly employee count

YearQtrEmployeesYoY ChangeYoY %
2026Q140+17+4.1%
2025Q433+18+5.5%
2025Q332+19+5.5%
2025Q222+8+6.8%
2025Q123+10+0.1%
2024Q415+2+0.0%
2024Q313+0+0.0%
2024Q214+1+0.0%
2024Q113+1+0.0%
2023Q413+3+10.9%
2023Q313+4+11.3%
2023Q213+4+11.3%

See Inhibikase Therapeutics's complete headcount history, including quarterly breakdowns.

Get the Data

Inhibikase Therapeutics Employee Count by Region (2026)

North America accounts for the largest share of Inhibikase Therapeutics's global workforce with approximately 94% of total employees, followed by Western Europe.

Inhibikase Therapeutics employees by region

RegionEmployees% of Total
North America3294.2%
Western Europe25.8%

Drill into city-level data, hiring trends by region, and historic geographic shifts.

Unlock Geographic Data

Inhibikase Therapeutics Employee Count by Department (2026)

Inhibikase Therapeutics's employee groups are Finance and Operations (42.3%), Sales and Marketing (41.7%), and Engineering (16.0%).

Inhibikase Therapeutics employees by department

DepartmentEmployees% of Total
Finance and Operations1742.3%
Sales and Marketing1741.7%
Engineering616.0%

Compare Inhibikase Therapeutics's department mix to industry peers.

See Full Data

Inhibikase Therapeutics Employee Salary by Region (2026)

Inhibikase Therapeutics's average employee salary is $205,203 globally. Employees in North America receive the highest compensation.

Inhibikase Therapeutics median employee salary by region (USD)

RegionMedian Salary
North America$219,000

Unlock salary by role, level, and city — and compare to Inhibikase Therapeutics's industry peers.

Unlock Salary Data

Inhibikase Therapeutics Job Openings and Hiring Trends (2023-2026)

Interactive chart of Inhibikase Therapeutics annual active job postings from 2023 to 2026.
  • Inhibikase Therapeutics had 0 active job postings in 2026, a 0% no change (-1) from 2025.
  • Inhibikase Therapeutics had 1 active job postings in 2025, a 200.0% increase (+1) from 2024.
  • Inhibikase Therapeutics had 0 active job postings in 2024, a 0% no change from 2023.
  • Inhibikase Therapeutics had 0 active job postings in 2023, a 0% no change from 2022.
  • Hiring velocity in 2026: 0 new roles/month, up from 0 in 2025 and 0 in 2024.

Inhibikase Therapeutics's hiring activity held steady in 2026.

Track new postings per month, role-level demand, and hiring velocity vs. peers.

Unlock Hiring Data

Similar Companies

Frequently Asked Questions About Inhibikase Therapeutics

How fast is Inhibikase Therapeutics growing?
In 2026, Inhibikase Therapeutics's headcount grew 4.1% to 40 employees, up from 23 in 2025.
See the full headcount history
Where are Inhibikase Therapeutics employees located?
Most Inhibikase Therapeutics employees are based in North America (94.2% of headcount), followed by Western Europe.
Explore where the workforce is based
What is the average salary at Inhibikase Therapeutics?
The average employee salary at Inhibikase Therapeutics is approximately $205.2k per year.
Analyze the salary distribution
How many new job postings does Inhibikase Therapeutics open per year?
In Q1 2026, Inhibikase Therapeutics opened 0 new job postings. In 2025, Inhibikase Therapeutics opened 3 new job postings — about 0 per month.
Track hiring trends by role
When was Inhibikase Therapeutics founded and where is it headquartered?
Inhibikase Therapeutics was founded in 2008 and is headquartered in Wilmington, Delaware.
Compare Inhibikase Therapeutics to industry peers

Speak with a workforce expert about Inhibikase Therapeutics.

Book a Demo

See something that doesn't look right? Reach out and our team will review it.